Detalles de la búsqueda
1.
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
Blood
; 137(13): 1818-1827, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150384
2.
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
Haemophilia
; 27(3): e331-e339, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33772963
3.
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Haemophilia
; 26(4): e168-e178, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32597029
4.
Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
Haemophilia
; 26(3): 478-486, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338433
5.
Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Haemophilia
; 25(5): 773-781, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31353761
6.
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Blood Adv
; 8(11): 2726-2739, 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38564770
7.
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
J Thromb Haemost
; 22(1): 90-100, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717853
8.
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study.
Ther Adv Hematol
; 14: 20406207231178596, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37465396
9.
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Expert Rev Hematol
; 16(10): 793-801, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646148
10.
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.
Clin Appl Thromb Hemost
; 26: 1076029620950836, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32866032
11.
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Clin Appl Thromb Hemost
; 26: 1076029620946839, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32816519
12.
Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
Blood Res
; 54(3): 198-203, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31730687
13.
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.
Expert Rev Clin Pharmacol
; 8(2): 163-77, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25660348
14.
Antibody of the IgG2 Subclass, Actinobacillus actinomycetemcomitans, and Early-Onset Periodontitis.
J Periodontol
; 67 Suppl 3S: 317-322, 1996 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29539843
Resultados
1 -
14
de 14
1
Próxima >
>>